Rotavirus vaccine, live, oral - Biologic Drug Details

Summary for rotavirus vaccine, live, oral

Tradenames:	1
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for rotavirus vaccine, live, oral

Recent Clinical Trials for rotavirus vaccine, live, oral

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Sanofi Pasteur, a Sanofi Company	PHASE1
Johns Hopkins Bloomberg School of Public Health	Phase 4
Merck Sharp & Dohme Corp.	Phase 4

See all rotavirus vaccine, live, oral clinical trials

Pharmacology for rotavirus vaccine, live, oral

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Live Attenuated Rotavirus Vaccine
Chemical Structure	Rotavirus Vaccines Vaccines, Attenuated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for rotavirus vaccine, live, oral Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for rotavirus vaccine, live, oral Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Biologicals	ROTARIX	rotavirus vaccine, live, oral	For Suspension	125265	10,016,338	2036-12-20	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals	ROTARIX	rotavirus vaccine, live, oral	For Suspension	125265	10,577,154	2038-12-19	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals	ROTARIX	rotavirus vaccine, live, oral	For Suspension	125265	10,912,714	2038-07-09	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals	ROTARIX	rotavirus vaccine, live, oral	For Suspension	125265	4,571,385	2003-06-27	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals	ROTARIX	rotavirus vaccine, live, oral	For Suspension	125265	4,704,275	2005-08-26	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals	ROTARIX	rotavirus vaccine, live, oral	For Suspension	125265	4,751,080	2007-07-31	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for rotavirus vaccine, live, oral Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Biologicals	ROTARIX	rotavirus vaccine, live, oral	For Suspension	125265	10,016,338	2036-12-20	Patent claims search
Glaxosmithkline Biologicals	ROTARIX	rotavirus vaccine, live, oral	For Suspension	125265	10,577,154	2038-12-19	Patent claims search
Glaxosmithkline Biologicals	ROTARIX	rotavirus vaccine, live, oral	For Suspension	125265	10,912,714	2038-07-09	Patent claims search
Glaxosmithkline Biologicals	ROTARIX	rotavirus vaccine, live, oral	For Suspension	125265	9,554,968	2034-03-11	Patent claims search
Glaxosmithkline Biologicals	ROTARIX	rotavirus vaccine, live, oral	For Suspension	125265	9,662,450	2034-02-28	Patent claims search
Glaxosmithkline Biologicals	ROTARIX	rotavirus vaccine, live, oral	Suspension	125265	10,016,338	2036-12-20	Patent claims search

International Patents for rotavirus vaccine, live, oral

Country	Patent Number	Estimated Expiration
South Korea	20210150615
South Korea	20180100710
Portugal	2251454
European Patent Office	2251455
Australia	2012318242
China	103357005

Market Dynamics and Financial Trajectory for Live Oral Rotavirus Vaccines

Last updated: February 23, 2026

What Are the Primary Drivers of Market Growth?

The global rotavirus vaccine market is expanding due to increased pediatric immunization efforts and rising awareness about rotavirus-induced diarrhea. The World Health Organization recommends universal vaccination, prompting governments to incorporate rotavirus vaccines into national immunization programs.

The key factors influencing market growth include:

• Increased Adoption in Low- and Middle-Income Countries (LMICs): High burden of rotavirus-related Infant mortality prompts government mandates and international funding, such as Gavi, the Vaccine Alliance.
• Introduction of Pediatric Vaccine Programs: Countries like India, Nigeria, and Indonesia expand immunization schedules, boosting demand.
• Safety and Efficacy Improvements: Newer formulations and dosing schedules enhance confidence among healthcare providers.
• Emergence of Spin-off and Combination Vaccines: Development of combination vaccines (e.g., with cholera or polio) provides options for integrated immunization.

What Are the Leading Products and Competitive Landscape?

Major players include:

Company	Product Name	Approval Status	Market Share (Estimate)	Notable Features
Merck & Co. (GSK)	Rotarix	Approved worldwide	40-45%	Live attenuated, oral, two-dose schedule
Sanofi	Rotateq	Approved in key markets	30-35%	Pentavalent, oral, three-dose schedule
Serum Institute	Rotavac	Approved in India	10-15%	Low-cost, live, oral, two-dose schedule
Others	Rotasiil, Rotavac	Approved in select markets	5-10%	Focus on affordability and accessibility

The market remains concentrated among these primary manufacturers, with GSK and Merck holding approximately 70-75% combined global share.

How Do Regulatory and Policy Factors Impact Financials?

Regulatory approvals influence market penetration. WHO prequalification enables vaccine distribution in LMICs. Policy decisions, such as inclusion in national immunization programs, directly impact revenues.

Gavi support in eligible countries bolsters volume sales but constrains pricing. Reimbursement policies vary sharply across regions, affecting profit margins.

What Are Projected Revenue and Market Size Trends?

The global rotavirus vaccine market, valued at approximately US$1.5 billion in 2021, is projected to grow at a compound annual growth rate (CAGR) of 7-9% through 2030, reaching about US$3 billion.

Forecast factors:

• Regional Expansion: Asia-Pacific region to grow at 10% CAGR due to high birth rates and immunization efforts.
• Product Lifecycle: Existing vaccines will see steady volume growth; new formulations are expected to stimulate renewal sales.
• Pricing Trends: Cost reductions from local manufacturing will enable increased accessibility, with expected pressure on per-dose prices.

What Future Market Trends Could Impact Financial Outcomes?

• Next-Generation Vaccines: Development of thermostable, fewer-dose regimens may drive adoption, especially in resource-limited settings.
• Combination Vaccines: Integration with other pediatric immunizations could streamline administration, increasing overall vaccine market penetration.
• Public-Private Partnerships: These will facilitate distribution and affordability, intensifying competition.
• Biosimilar Entry: Entry of biosimilars may reduce prices, pressuring traditional manufacturers’ margins.

How Are External Factors Affecting the Market?

• Pandemic Impact: COVID-19 disrupted routine immunizations, but recovery is underway, potentially accelerating future growth.
• Economic Conditions: Healthcare spending in LMICs may influence procurement budgets.
• Policy Changes: Mandatory vaccination laws increase uptake but may also limit pricing flexibility.

Key Financial Insights

• Pricing: US$3–US$10 per dose in high-income countries; US$0.50–US$2 in LMICs.
• Cost Structure: Production costs range from US$0.10–US$0.50 per dose; higher R&D expenses for new formulations.
• Profit Margins: Gross margins are approximately 60–70%, influenced heavily by manufacturing scale and regional pricing strategies.
• Revenue Concentration: Top 3 manufacturers account for about 75% of market revenue, with the remainder split among regional players.

Conclusion

The rotavirus vaccine market exhibits steady growth driven by high burden regions, policy mandates, and innovations in vaccine formulations. Competitive dynamics are characterized by a handful of dominant players maintaining high margins, while regional policies and affordability efforts shape revenue streams. Upcoming innovations in vaccine technology and distribution models are poised to influence the market well into the next decade.

---

Key Takeaways

• The global market for live oral rotavirus vaccines is projected to reach US$3 billion by 2030, with a CAGR of 7-9%.
• Major players, Merck, GSK, and Serum Institute, control approximately 75% of sales.
• Market expansion is driven by government policies, international aid, and technological innovations.
• Pricing varies from US$0.50 to US$10 per dose, affecting margins and profitability.
• Future growth relies on new formulations, combination vaccines, and expanded access in LMICs.

---

FAQs

1. What factors limit the growth of rotavirus vaccines in certain regions?
   Regulatory barriers, supply chain challenges, and budget constraints in LMICs impact vaccine adoption.

2. How do new vaccine formulations influence pricing strategies?
   Variations such as thermostable, fewer-dose regimens are priced competitively, aiming to increase affordability and access.

3. What role do government and international agencies play in market dynamics?
   They influence volume growth through policy mandates, funding, and procurement agreements.

4. Are biosimilars a threat to established vaccine manufacturers?
   While biosimilars could reduce prices, their impact depends on regulatory approval, manufacturing capacity, and market acceptance.

5. How will technological advancements shape future market revenues?
   Innovations like thermostability and combination vaccines are central to expanding access and volume, expanding revenue potential.

---

References

[1] WHO. (2022). Rotavirus vaccines: WHO position paper. Weekly Epidemiological Record.